Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Barclays PLC

Barclays PLC raised its position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 132.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 120,464 shares of the company’s stock after purchasing an additional 68,688 shares during the period. Barclays PLC owned 0.12% of Poseida Therapeutics worth $345,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PSTX. Fred Alger Management LLC acquired a new position in shares of Poseida Therapeutics during the third quarter worth approximately $369,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Poseida Therapeutics by 62.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock worth $1,027,000 after purchasing an additional 138,510 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after purchasing an additional 297,500 shares during the period. Advantage Alpha Capital Partners LP bought a new stake in shares of Poseida Therapeutics during the third quarter valued at about $285,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Poseida Therapeutics by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 567,063 shares of the company’s stock valued at $1,622,000 after purchasing an additional 21,255 shares in the last quarter. Institutional investors own 46.87% of the company’s stock.

Insider Transactions at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the completion of the sale, the chairman now directly owns 651,291 shares of the company’s stock, valued at approximately $6,161,212.86. This represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.90% of the company’s stock.

Poseida Therapeutics Price Performance

PSTX stock opened at $9.50 on Monday. The firm has a market cap of $928.85 million, a PE ratio of -15.08 and a beta of 1.63. Poseida Therapeutics, Inc. has a 12 month low of $1.87 and a 12 month high of $9.67. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. The firm has a 50 day simple moving average of $8.04 and a 200 day simple moving average of $4.71.

Analyst Ratings Changes

Several research firms have commented on PSTX. Cantor Fitzgerald cut shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. HC Wainwright reiterated a “neutral” rating and set a $9.00 price objective (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Piper Sandler downgraded Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 target price for the company. in a research report on Monday, December 2nd. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.50.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.